Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Combination angiotensin receptor blocker-neutral endopeptidase inhibitor provides additive blood pressure reduction over angiotensin receptor blocker alone.

× No keyword cloud information.

6 in total

1. Assessment of Drug-Drug Interaction Potential Between Atorvastatin and LCZ696, A Novel Angiotensin Receptor Neprilysin Inhibitor, in Healthy Chinese Male Subjects.

Authors: Surya Ayalasomayajula; Wei Pan; Yi Han; Fan Yang; Thomas Langenickel; Parasar Pal; Wei Zhou; Yaozong Yuan; Iris Rajman; Gangadhar Sunkara
Journal: Eur J Drug Metab Pharmacokinet Date: 2017-04 Impact factor: 2.441

Review 2. Drug discovery in renin-angiotensin system intervention: past and future.

Authors: Bryan Williams
Journal: Ther Adv Cardiovasc Dis Date: 2016-04-27

3. Pharmacokinetics, Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese Subjects.

Authors: Yi Han; Surya Ayalasomayajula; Wei Pan; Fan Yang; Yaozong Yuan; Thomas Langenickel; Markus Hinder; Sampath Kalluri; Parasar Pal; Gangadhar Sunkara
Journal: Eur J Drug Metab Pharmacokinet Date: 2017-02 Impact factor: 2.441

4. Sacubitril/valsartan instead of renin-angiotensin system inhibition alone: A step forward in resistant hypertension.

Authors: Konstantinos Stavropoulos; Konstantinos P Imprialos; Michael Doumas
Journal: J Clin Hypertens (Greenwich) Date: 2017-12-13 Impact factor: 3.738

5. How full is our antihypertensives pipeline?

Authors: Dilip Gude
Journal: J Pharmacol Pharmacother Date: 2012-01

6. Low dose sacubitril/valsartan is effective and safe in hemodialysis patient with decompensated heart failure and hypotension: A case report.

Authors: Yunlin Feng; Wenhua Li; Hongjun Liu; Xiuling Chen
Journal: Medicine (Baltimore) Date: 2022-04-15 Impact factor: 1.817

6 in total